Improvement of Blood Plasmalogens and Clinical Symptoms in Parkinson’s Disease by Oral Administration of Ether Phospholipids: A Preliminary Report

Table 4

Increase of erythrocyte plasmalogen in PD after administration of scallop-derived ether phospholipids.

Variable (%)	Before	After 12 weeks	value	After 24 weeks	value
plsPE	7.67 (0.78)	8.43 (1.2)	0.03	8.64 (0.97)	0.01
PE	9.71 (0.81)	10.12 (0.77)	0.32	10.81 (0.95)	0.03
PC	23.25 (1.74)	23.54 (3.29)	0.83	25.41 (1.74)	0.006
SM	49.99 (3.1)	47.87 (5.41)	0.39	44.83 (2.65)	0.004
PS	9.34(1.14)	10.05 (1.08)	0.13	10.33 (0.75)	0.01

Values are mean (SD) unless otherwise specified. plsPE: ethanolamine plasmalogen; PE: diacyl ethanolamine glycerophospholipid; PC: diacyl choline glycerophospholipid; PS: diacyl serine glycerophospholipid; SM: sphingomyelin. Differences from immediate before trial.